Covid-19 roundup: US buys more of the on­ly an­ti­body that works against Omi­cron; BioN­Tech taps AI to de­tect new vari­ants faster

Glax­o­SmithK­line and Vir’s mon­o­clon­al an­ti­body sotro­vimab is still the on­ly mAb treat­ment that works against the Omi­cron vari­ant, and the US on Tues­day boost­ed its sup­ply again.

This lat­est deal, the fi­nan­cial de­tails of which were not im­me­di­ate­ly dis­closed, will bring 600,000 ad­di­tion­al dos­es to the US, ready for dis­tri­b­u­tion this quar­ter. GSK and Vir pre­vi­ous­ly land­ed two pri­or pro­cure­ment deals that amount­ed to about $1 bil­lion in sotro­vimab sold. GSK said it’s now signed agree­ments for ship­ping 1.7 mil­lion dos­es of sotro­vimab world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER